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INTRODUCTION
Tumor cells often exhibit alterations in chromosome number 
and/or structure. Studies of cells in metaphase enable detec-
tion of these alterations. However, archived samples cannot 
be used for this approach, and access to proliferating tumor 
cells for metaphase analysis can be difficult, especially when 
attempting to culture cells from solid tumors. Comparative 
genomic hybridization (CGH), described in 1992, allows 
comparison between tumor and normal cell genomes by dif-
ferentially labeling each and cohybridizing them on slides 
containing normal metaphase cells. This technique makes it 
possible to detect common regions of genomic deletion and 
amplification within archived tumor samples. However, ini-
tially the resolution was limited to large genomic changes vis-
ible on metaphase chromosomes. To improve the resolution, 
human metaphase chromosomes were replaced by an array 
or matrix on a chip of bacterial artificial chromosome (BAC) 
clones generated using human genome fragments. These 
were later replaced by commercially available 25–70 base 
pair–long oligonucleotides, which provide high accuracy and 
reproducibility. Here, we explain these approaches, known 
as array CGH or single-nucleotide polymorphism array (SNP 
array), highlighting their benefits, limitations, and potential 
applications and discussing their future in view of now widely 
available next-generation sequencing (NGS) techniques.
Array CGH and SNP arrays have been used extensively to 
analyze copy-number alterations in tumor DNA. Both tech-
niques provide a genome-wide screening tool to identify dele-
tions and amplifications, and SNP arrays also allow allelotyp-
ing. Array approaches are used to search for causative consti-
tutional (germline) and acquired genomic alterations in carci-
nogenesis. These techniques were utilized to identify recurrent 
copy-number alterations in tumors and led to the identifica-
tion of novel oncogenes and tumor suppressor genes. Results 
from array-CGH studies have been important for the subclas-
sification of dermatological malignancies and identification of 
novel potential prognostic markers and genomic alterations 
involved in dermatological disease pathogenesis.
HOW ARRAY TECHNIQUES WORK
In array approaches, probes corresponding to genom-
ic regions are immobilized onto a glass surface, form-
• Is a genome-wide screening tool. 
• Interrogates hundreds of thousands to millions of 
 probes in a single experiment.
• Detects tumor-associated genomic changes with 
 copy-number alterations (gains/amplifications and 
 losses/deletions).
• Probes designed for single-nucleotide 
 polymorphism loci allow allelotyping.
• Requires large, up-front investment in equipment 
 (hybridization, imaging of slides). 
• Balanced rearrangements are not detected.
• Single-nucleotide changes (pathogenic mutations) 
 will not be detected.
• Studies a mixed pool of cells, so there are 
 limitations detecting changes in cases of normal 
 cell infiltration and high tumor heterogeneity. 
• Does not provide data on expression levels of 
 genes involved in the gains or amplifications.
WHAT GENOMIC ARRAY DOES
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ing the detection chip. Isolated and fluorescently labeled 
test DNA is then competitively hybridized to these chips 
and any unbound DNA is stringently removed by washing. 
Fluorescence intensities are scanned by an imager and corre-
spond to the copy number of each interrogated loci (probe). 
In contrast to fluorescence in situ hybridization (FISH), which 
generates data about genomic loci at a single-cell level, 
genomic array approaches provide information about pools 
of cells, albeit without morphological context.
ARRAY CGH VERSUS SNP ARRAY
For array CGH, the labeled test sample is mixed with a differ-
ently labeled reference DNA sample that typically consists of 
a pool of DNA isolated from several healthy donors. The use 
of a normal reference DNA sample allows easy normaliza-
tion within one experiment (Figure 1, left). 
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For SNP array, reporter oligonucleotides, also known as 
allele-specific oligonucleotides, are designed to detect known 
single-nucleotide differences, selected from all known variants 
for the interrogated sequence. In an SNP-array experiment, a 
single test sample is hybridized to a chip and detected with a 
single label (Figure 1, right). With bioinformatics algorithms, 
SNPs can be identified and the respective copy number can 
be deciphered. Detection of both loss of heterozygosity (LOH) 
and copy-neutral anomalies, such as uniparental disomy or 
homozygosity, becomes feasible using SNP arrays (Figure 1, 
right). Use of DNA derived from both tumor and normal tissue 
from the same patient is necessary to draw conclusions about 
tumor-associated changes. 
Finally, normalized fluorescence ratios are then ordered 
based on their genomic position and displayed as a molecular 
karyogram (Figure 2a). 
ADVANCES IN ARRAY APPROACHES 
Multitarget detection and wide range in copy-number detection 
capability
In contrast to targeted approaches such as FISH or quantita-
tive, locus-specific PCR, an array experiment allows simul-
taneous testing of thousands of loci, allowing genome-wide 
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Figure 1.  Overview of genomic array-based procedures. The left panel 
shows array-comparative genomic hybridization (array CGH), whereas 
the right panel shows single-nucleotide polymorphism (SNP) array. Array 
CGH utilizes differentially labeled test and reference DNAs, whereas SNP 
array uses labeled single test samples. In both cases, samples are mixed 
with repeat suppressor C0t-1 DNA and hybridized to detection chips. 
After hybridization and stringent washing, array chips are scanned by a 
fluorescence laser scanner and intensity values are further processed. 
Resulting data files are analyzed for changes in chromosomes and DNA base 
positions. The resolution of the array is largely determined by the reporter 
probe density. The lower left panel shows superimposed results using either 
an ~3.5-kb bacterial artificial chromosome (BAC) probe array (black dots) 
or a 244-kb oligonucleotide probe array (gray dots). The blue arrowhead 
indicates a small triplicated region undetected by the BAC array. The lower 
right panel shows results from a SNP array showing the copy number of the 
displayed chromosome (lower inset), indicating no copy-number alteration. 
In the upper inset, B-allele frequency is displayed. Because most of the SNP 
should be heterozygous, here the allele frequency should be expected to be 
0.5. Loss of heterozygosity (LOH) would lead to either the lack of B alleles 
(0) or two B alleles (1.0). The red arrowheads mark large regions of LOH 
without corresponding copy-number alterations, a phenomenon known as 
copy number–neutral LOH.
Figure 2. Array CGH identified a high level of amplification and 
homozygous losses in primary cutaneous large B-cell lymphomas. (a) 
Genome-wide overview of multiple primary cutaneous large B-cell 
lymphoma cases. (b) The most frequent high level of amplification involved 
the chromosome 2p16.1 region where BCL11A and REL genes reside. (c) 
Interphase: fluorescence in situ hybridization (FISH) verification of the REL 
amplification using REL (green) and CDK4 (red) region-specific probes. The 
numerous loci of green signal correspond to the amplification detected by 
array CGH. Reprinted with permission from Dijkman et al. (2006).
screening of copy-number alterations. Further, the relative 
number of altered copies of loci can be determined, ranging 
from a homozygous deletion to a high number of amplifica-
tions, since the fluorescence signal intensity is linearly pro-
portional to the number of tested molecules.
Heterogeneous populations
Rigorous quality measures allow detection of genomic 
changes present in low frequency (8–10%) in a heteroge-
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neous population using array approaches. Examples include 
mosaicism found when studying constitutional genetics, 
intratumor heterogeneity, or tumor samples infiltrated with 
normal cells (Szuhai et al., 2011).
LIMITATIONS OF ARRAY TECHNOLOGIES
Resolution
The resolution of array technologies is determined by the 
probe density. A higher density allows more precise detec-
tion of small genomic changes, but may increase cost per 
analyzed sample and background, such as detection of chro-
mosomal copy-number variations with unknown clinical sig-
nificance (Figure 1, left) (Knijnenburg et al., 2007). At pres-
ent, the costs for NGS tests are similar to costs for array-based 
experiments, with several advantages of NGS over genomic 
arrays, including the ability to identify balanced genomic 
rearrangements and small mutations. For example, exome 
sequencing combined with the proper analysis algorithm 
generates a genome-wide copy-number profile, allelotyp-
ing, and details on single-nucleotide changes (Grada and 
Weinbrecht, 2013). Increased use of targeted sequencing-
based approaches could further decrease test-related costs 
and detect all relevant gene mutations, copy-number chang-
es, and translocation breakpoints (Cheng et al., 2015).
Spatial organization 
Detecting genetic copy-number changes will not reveal 
information about the spatial organization of the involved 
chromosomes. For example, an unbalanced translocation 
will appear as a loss and gain of the involved chromosomal 
regions, but nothing about their physical association will 
be revealed. Similarly, balanced genomic rearrangements 
including balanced translocations among chromosomes, 
chromosomal insertions, and intrachromosomal changes 
like inversions cannot be detected using array approaches.
Sample availability
DNA isolated from fresh-frozen tissues is preferred for array 
techniques because DNA isolated from formalin-fixed, par-
affin-embedded tissue blocks may have undergone degrada-
tion, leading to nonuniform sample labeling with fluorescent 
nucleotides. 
For accurate detection of genomic alterations, samples 
with as high tumor content as possible (>50% or, ideally, 
80–90% or higher) should be selected. The detection sensi-
tivity depends not only on a high tumor content, but also on 
the ploidy of tumor cells. Because of the normalization pro-
cess, samples with tetraploid DNA content will show only 
half the dynamic range for alterations compared with those 
with a diploid DNA content.
DATA INTERPRETATION
For array CGH, where the ratio of the test and reference 
samples is taken from the same hybridization reaction, 
internal normalization happens immediately, assuming that 
no great quality differences were present between the test 
and reference DNA. For SNP arrays, each measurement is 
compared and normalized to a previously generated exter-
nal reference. Fluctuations in actual test quality may there-
fore have a stronger effect.
Various statistical approaches can then be applied to nor-
malize the data across the whole genome. The obtained ratios 
are often displayed as Log 2 values to help detect gains and 
losses. Results are displayed according to chromosome and 
genomic positions (Figure 1).
Validation
Resulting data can be validated using other techniques, 
such as quantitative real-time PCR or FISH (Figure 2). 
Multiplex ligation-based probe assays can be used to ver-
ify up to 40 loci in a single reaction. However, for novel 
findings new probes may need to be designed, and FISH 
probes may not have the resolution to confirm results from 
array-based approaches. For example, gains and deletions 
of 5–10 kb can be readily detected by array approach-
es, whereas most FISH probes generated from BACs are 
between 80 and 200 kb. Gains or duplications, especial-
ly small tandem duplications, may also not be detectable 
using FISH probes.
USE OF GENOMIC ARRAYS IN DERMATOLOGY
Genomic array approaches have made major contributions 
to understanding dermatological cancers. In melanoma, 
array-CGH approaches revealed that increased chromo-
somal instability is associated with poor clinical outcome 
(Hirsch et al., 2013). In addition, array-CGH studies uncov-
ered homozygous deletions of the tumor suppressor genes 
CDKN2A and PTEN and amplifications of oncogenes MITF, 
CCND1, and MDM2, suggesting that these copy-number 
alterations play a role in the pathogenesis of melanoma since 
these genes regulate increased cell cycle progression and 
resistance to apoptosis (Stark and Hayward, 2007). 
Extensive genetic instability and recurrent copy-number 
alterations were found in Sézary syndrome (SS) using array 
CGH, including gain of MYC, loss of the MYC antagonists 
MXI1 and MNT, loss of TP53, and gain of STAT3/STAT5 and 
IL-2-receptor genes. These results suggest that increased 
MYC expression combined with impaired MYC-induced 
apoptosis and increased STAT signaling play a role in the 
pathogenesis of SS (Vermeer et al., 2008). 
SS is often considered a leukemic phase of mycosis fun-
goides (MF). However, substantial genomic differences 
between SS and MF were found using array-CGH and gene 
expression microarrays, suggesting a distinct molecular 
pathogenesis. Furthermore, a high number of DNA altera-
tions, specifically gains of 8q24.21 and losses of 9p21.3 and 
10q26qter, were found to be associated with poor prognosis 
in MF (Salgado et al., 2010; van Doorn et al., 2009). 
Array-CGH and gene expression studies were impor-
tant in supporting the subclassification of primary cutane-
ous large B-cell lymphomas into primary cutaneous fol-
licle center lymphoma (PCFCL) and primary cutaneous 
large B-cell lymphoma (PCLBCL), leg type. This distinction 
is clinically important because PCFCL has a good progno-
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sis and can be treated with radiotherapy, whereas PCLBCL, 
leg type, has a poor prognosis (5-year survival of 40%) and 
should be treated with chemotherapy. A high level of ampli-
fication of the chromosome 2p16.1 region was observed 
in 60% of PCFCL cases, involving BCL11A and REL genes 
(Figure 2). Homozygous CDKN2A deletion is associated 
with poor prognosis in PCLBCL, leg type (Dijkman et al., 
2006; Senff et al., 2009). These studies highlight how array-
CGH data have been used in the subclassification of derma-
tological malignancies and have identified potential prog-
nostic markers and genomic alterations that may play a role 
in the pathogenesis of these diseases.
SUMMARY AND FUTURE PROSPECTS
Genomic array testing allows detection of genetic copy-num-
ber changes and, in the case of SNP array, allelic changes. 
Results from genomic array tests have been important in 
the identification of underlying copy-number alterations in 
microdeletion/microduplication syndromes and in char-
acterizing acquired genetic alterations in malignancies. 
Collected, publicly accessible array profiles could serve as 
references to gain a broader understanding of the genetic eti-
ologies underlying disease. However, in our view, genomic 
array techniques will likely soon be overtaken by NGS-based 
approaches to uncover unknown genomic changes or gener-
ate novel diagnostic tests.
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1. Comparative genomic hybridization is a tool that 
 is suited to 
A. Detect copy-number alterations.
B. Detect translocations.
C. Give information about gene expression. 
2. A genomic array-CGH profile without any 
 detectable alteration indicates
A. The lack of tumor cells.
B. Copy number–neutral LOH.
C. Balanced rearrangements.
D. Probe density that is too low.
3. Array CGH is preferably performed using 
 DNA obtained from 
A. Frozen tissue with low tumor content.
B. Paraffin-embedded tissue with low tumor 
 content.
C. Frozen tissue with high tumor content.
D. Paraffin-embedded tissue with high tumor 
 content.
4. Major advances in array approaches do not include 
 the following:
A. Multiple genetic loci are investigated in one 
 experiment.
B. A wide dynamic range in copy-number 
 estimation allows for detection of gains 
 and losses.
C. Array CGH can be performed on heterogeneous 
 cell populations. 
D. Information on spatial organization of the 
 involved chromosomes.
5. The resolution for the detection of copy-number 
 alterations depends largely on
A. The probe density on a chip.
B. The software that is used.
C. The DNA quality of the samples.
D. The amount of available sample DNA.
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